Heritage Cannabis Holdings Past Earnings Performance
Past criteria checks 0/6
Heritage Cannabis Holdings's earnings have been declining at an average annual rate of -30.5%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 50.5% per year.
Key information
-30.5%
Earnings growth rate
-5.5%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | 50.5% |
Return on equity | -96.4% |
Net Margin | -67.4% |
Last Earnings Update | 31 Oct 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Heritage Cannabis Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Oct 23 | 30 | -20 | 16 | 0 |
31 Jul 23 | 30 | -33 | 19 | 0 |
30 Apr 23 | 29 | -35 | 19 | 0 |
31 Jan 23 | 29 | -33 | 17 | 0 |
31 Oct 22 | 30 | -24 | 17 | 0 |
31 Jul 22 | 26 | -40 | 13 | 0 |
30 Apr 22 | 23 | -44 | 14 | 0 |
31 Jan 22 | 19 | -48 | 14 | 0 |
31 Oct 21 | 14 | -57 | 13 | 0 |
31 Jul 21 | 11 | -20 | 11 | 0 |
30 Apr 21 | 9 | -13 | 8 | 0 |
31 Jan 21 | 6 | -10 | 7 | 0 |
31 Oct 20 | 8 | -9 | 6 | 0 |
31 Jul 20 | 10 | -4 | 8 | 0 |
30 Apr 20 | 8 | -8 | 10 | 0 |
31 Jan 20 | 7 | -11 | 11 | 0 |
31 Oct 19 | 4 | -13 | 12 | 0 |
31 Jul 19 | 0 | -14 | 11 | 0 |
30 Apr 19 | 0 | -11 | 9 | 0 |
31 Jan 19 | 0 | -8 | 8 | 0 |
31 Oct 18 | 0 | -6 | 7 | 0 |
31 Jul 18 | 0 | -4 | 6 | 0 |
30 Apr 18 | 0 | -3 | 5 | 0 |
31 Jan 18 | 0 | -2 | 4 | 0 |
31 Oct 17 | 0 | 0 | 2 | 0 |
31 Jul 17 | 0 | -2 | 1 | 0 |
30 Apr 17 | 0 | -2 | 2 | 0 |
31 Jan 17 | 0 | -1 | 1 | 0 |
31 Oct 16 | 0 | -1 | 1 | 0 |
31 Jul 16 | 0 | -1 | 1 | 0 |
30 Apr 16 | 0 | -1 | 1 | 0 |
31 Jan 16 | 0 | -1 | 1 | 0 |
31 Oct 15 | 0 | -1 | 1 | 0 |
31 Jul 15 | 0 | -2 | 1 | 0 |
30 Apr 15 | 0 | -2 | 1 | 0 |
31 Jan 15 | 0 | -2 | 1 | 0 |
31 Oct 14 | 0 | -2 | 1 | 0 |
31 Jul 14 | 0 | 0 | 0 | 0 |
30 Apr 14 | 0 | 0 | 0 | 0 |
31 Jan 14 | 0 | -1 | 0 | 0 |
31 Oct 13 | 0 | 0 | 0 | 0 |
31 Jul 13 | 0 | -1 | 0 | 0 |
Quality Earnings: 2UE is currently unprofitable.
Growing Profit Margin: 2UE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2UE is unprofitable, and losses have increased over the past 5 years at a rate of 30.5% per year.
Accelerating Growth: Unable to compare 2UE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2UE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: 2UE has a negative Return on Equity (-96.37%), as it is currently unprofitable.